免疫檢查點抑制劑在血液惡性腫瘤的進展

10.6666/ClinMed.2017.80.3.097

陳三奇；劉俊煌

免疫檢查點抑制劑(checkpoint inhibitor) ； CTLA-4(cytotoxic T-lymphocyte associated protein 4 ) ； PD - 1 (programmed death protein 1) ； PD - L1(programmed death-ligand 1)

臨床醫學月刊

80卷3期（2017 / 09 / 29）

523 - 527

繁體中文

本文介紹了免疫檢查點抑制劑在血液惡性腫瘤的進展，目前成效最顯著的是應用在何杰金氏淋巴癌的治療，對於已經使用過多重藥物仍復發的患者，仍有超過一半以上的有效率，對於非何杰金氏淋巴癌包括：瀰漫性大型B細胞淋巴癌、濾泡型淋巴瘤，臨床試驗的結果也顯示免疫檢查點抑制劑對部分患者具有療效，值得注意的是，在接受自體幹細胞移植後(post-autologous stem cell transplantation)的瀰漫性大型B細胞淋巴癌患者，也可能因為接受免疫檢查點抑制劑而減少復發的機會。至於接受異體幹細胞移植後(post-allogeneic stem cell transplantation)復發的血液惡性腫瘤患者，也有部分病患在使用免疫檢查點抑制劑後達到完全緩解，而且僅有少數患者因為免疫相關副作用導致死亡。目前大部分的報告都是來自於第一、二期臨床試驗結果，免疫檢查點抑制劑在血液惡性腫瘤的應用，還需要未來更多研究來支持。

1. Ansell, SM,Hurvitz, SA,Koenig, PA(2009).Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Clin Cancer Res,15,6446-6453.
2. Ansell, SM,Lesokhin, AM,Borrello, I(2015).PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.N Engl J Med,372,311-319.
3. Armand, P(2015).Immune checkpoint blockade in hematologic malignancies.Blood,125,3393-3400.
4. Armand, P,Nagler, A,Weller, EA(2013).Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.J Clin Oncol,31,4199-4206.
5. Armand, P,Shipp, MA,Ribrag, V(2016).Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure.J Clin Oncol,34,3733-3740.
6. Berger, R,Rotem-Yehudar, R,Slama, G(2008).Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.Clin Cancer Res,14,3044-3051.
7. Davids, MS,Kim, HT,Bachireddy, P(2016).Ipilimumab for Patients with Relapse after Allogeneic Transplantation.N Engl J Med,375,143-153.
8. Green, MR,Monti, S,Rodig, SJ(2010).Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood,116,3268-3277.
9. Green, MR,Rodig, S,Juszczynski, P(2012).Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.Clin Cancer Res,18,1611-1618.
10. Keir, ME,Butte, MJ,Freeman, GJ,Sharpe, AH(2008).PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol,26,677-704.
11. Lesokhin, AM,Ansell, SM,Armand, P(2014).Preliminary results of a phase I study of nivolumab(BMS-936558) in patients with relapsed or refractory lymphoid malignancies.Blood,124,291.
12. Saha, A,Aoyama, K,Taylor, PA(2013).Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.Blood,122,3062-3073.
13. Westin, JR,Chu, F,Zhang, M(2014).Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.Lancet Oncol,15,69-77.
14. Yang, H,Bueso-Ramos, C,DiNardo, C(2014).Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Leukemia,28,1280-1288.